Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Vertex Pharmaceuticals Incorporated (VRTX) had Normalized Pre-Tax Income of $4.64B for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$12.00B |
|
$3.95B |
|
$1.65B |
|
$10.35B |
|
$7.83B |
|
$4.17B |
|
$469.90M |
|
$4.64B |
|
|
Normalized Pre-Tax Income |
$4.64B |
$3.95B |
|
$3.95B |
|
$3.95B |
|
$3.95B |
|
$4.17B |
|
$4.17B |
|
255.70M |
|
258.00M |
|
$15.46 |
|
$15.32 |
|
| Balance Sheet Financials | |
$11.20B |
|
$1.52B |
|
$14.44B |
|
$25.64B |
|
$3.86B |
|
-- |
|
$3.12B |
|
$6.98B |
|
-- |
|
$17.15B |
|
$18.67B |
|
254.00M |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|